Michael T. Campoli

Pryor Cashman recently represented Javelin Pharmaceuticals in a registered direct offering of 3,186,700 shares of common stock to a single investor, raising gross proceeds of approximately $3.9 million.

Javelin Pharmaceuticals is a leading developer and marketer of specialty pharmaceutical products for pain management.

The Pryor Cashman team was led by Partners Jeffrey Johnson and Richard Frazer, along with associates Michael Campoli and David Parsly.